Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Summary not available.
Philip Morris International (NYSE:PM) presented its growth strategy in a virtual investor meeting, reaffirming its 2021 diluted EPS forecast between $5.90 and $6.00, a projected 14% to 16% increase from 2020. The company set ambitious targets for 2021-2023, aiming for over 5% organic growth in net revenue and over 9% in adjusted diluted EPS. Upcoming product launches include IQOS ILUMA and IQOS VEEV. PMI expects smoke-free products to surpass 50% of net revenues by 2025 and aims for $1 billion in revenues from beyond nicotine products by the same year.
Philip Morris International (PMI) has appointed Bonin Bough as a new member of its Board of Directors, effective immediately. Bough, aged 43, is a well-regarded executive with experience in growth and marketing at notable companies like Unilever and Mondelez International. Interim Chairman Lucio Noto welcomed Bough, emphasizing the importance of digital expertise in PMI's mission to transition to smoke-free products. PMI is committed to replacing cigarettes with smoke-free alternatives and has made significant strides, with approximately 12.7 million adults globally having switched to its IQOS device.
Philip Morris International Inc. (NYSE:PM) reported its 2020 fourth-quarter and full-year results, showcasing resilience amid the COVID-19 pandemic. Full-year reported diluted EPS rose 11.9% to $5.16, while adjusted diluted EPS declined slightly by 0.4% to $5.17. Total shipments dropped by 8.1%, yet heated tobacco units surged by 27.6%. The company expanded its IQOS market share, ending 2020 with an estimated 17.6 million users. PMI forecasts mid-single-digit organic net revenue growth for 2021, projecting adjusted diluted EPS growth between 9% to 11%. The quarterly dividend was increased by 2.6% to $4.80.
Philip Morris International (PMI) will host a live video webcast for its 2021 Investor Day on February 10, 2021, from 8:30 a.m. to 1:30 p.m. ET. Senior management will present and engage in a Q&A session, accessible via www.pmi.com/2021InvestorDay. An archive of the session will be available until March 11, 2021, at 5:00 p.m. ET. PMI is focused on creating a smoke-free future, encouraging adult smokers to transition to smoke-free products, including the IQOS platform, which has already helped approximately 11.7 million smokers switch.
Philip Morris International Inc. (PMI) has signed a memorandum of understanding with the U.S. Department of Homeland Security's National Intellectual Property Rights Coordination Center. This partnership aims to combat illicit tobacco trade and support investigations into intellectual property rights violations. PMI's head of illicit trade prevention emphasized the importance of this cooperation to disrupt criminal organizations profiting from this trade. The agreement builds on previous initiatives to enhance national security and protect consumers from illicit products.
Philip Morris International (NYSE: PM) will host a live audio webcast on February 4, 2021, at 10:30 a.m. ET to discuss its 2020 Fourth-Quarter and Full-Year results. The results will be disclosed at 8:00 a.m. ET the same day. CFO Emmanuel Babeau will present the financial outcomes and the 2021 outlook, with Q&A from the CEO and COO. The event will be accessible in listen-only mode, and an archived version will be available until March 5, 2021. PMI focuses on a smoke-free future, with 11.7 million adult smokers having switched to its IQOS product.
Philip Morris International (PMI) has appointed Jorge Insuasty as Chief Life Sciences Officer, effective January 15, 2021. Insuasty, who has extensive experience in the pharmaceutical industry, succeeds John O’Mullane, who is retiring. CEO André Calantzopoulos highlighted Insuasty's transformational leadership and his role in advancing product portfolios. Insuasty previously held significant positions at Sanofi and Novartis, leading successful drug approvals and innovations. PMI aims to create a smoke-free future by replacing traditional cigarettes with smoke-free alternatives, benefiting adult smokers.
Philip Morris International (NYSE:PM) will redeem all outstanding 1.875% Notes due February 25, 2021, on January 25, 2021. As of December 15, 2020, $750 million in principal was outstanding. PMI will pay the registered holders 100% of the principal amount plus accrued interest. This release does not constitute a notice of redemption. PMI is transitioning to a smoke-free future, encouraging adult smoking cessation with its IQOS product, which has moved approximately 11.7 million adults to smoke-free alternatives across 61 markets. For more, visit www.pmi.com.